Menu
Search
|

Menu

Close
X

Alder Biopharmaceuticals Inc ALDR.OQ (NASDAQ Stock Exchange Global Market)

14.26 USD
+0.09 (+0.64%)
As of 5:08 PM GMT
chart
Previous Close 14.17
Open 14.24
Volume 27,198
3m Avg Volume 265,390
Today’s High 14.36
Today’s Low 14.15
52 Week High 20.85
52 Week Low 9.51
Shares Outstanding (mil) 67.71
Market Capitalization (mil) 863.35
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.31 Mean rating from 16 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
0
EPS (USD)
FY18
-3.685
FY17
-5.195
FY16
-3.222
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.70
Price to Sales (TTM)
vs sector
1,264.05
6.29
Price to Book (MRQ)
vs sector
2.93
5.26
Price to Cash Flow (TTM)
vs sector
--
24.98
Total Debt to Equity (MRQ)
vs sector
0.00
16.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.38
Return on Investment (TTM)
vs sector
-76.39
14.45
Return on Equity (TTM)
vs sector
-76.45
15.96

EXECUTIVE LEADERSHIP

Robert Azelby
President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Carlos Campoy
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Erin Lavelle
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Larry Benedict
Executive Vice President, Principal Accounting Officer, Since 2016
Salary: $343,804.00
Bonus: --
Elisabeth Sandoval
Chief Commercial Officer and Executive Vice President of Corporate Strategy, Since 2018
Salary: $385,168.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11804 N Creek Pkwy S
BOTHELL   WA   98011-8801

Phone: +1425.2052900

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

SPONSORED STORIES